Canakinumab is a human monoclonal anti-human interleukin (IL)-1β antibody used to treat a variety of immune inflammatory diseases. It can specifically bind to human IL-1β and block the interaction between human IL-1β and IL-1 receptors, reducing the occurrence of inflammatory responses. There are some matters that patients need to pay special attention to during use.

Precautions for Canakinumab

Canakinumab is a fully human monoclonal antibody. Patients need to pay special attention to the following matters when using it:

Severe infection

Canakinumab can reduce the ability of the immune system to fight infection. When using this drug, the risk of infection in patients will increase. When using Canakinumab, patients should be closely monitored for symptoms of infection and treated in a timely manner. The combined administration of other IL-1 blockers with TNF inhibitors has been found to be associated with an increased incidence of serious infections. Canakinumab is not recommended for combined use with TNF inhibitors. Before starting Canakinumab or other immunomodulatory treatments, patients should be evaluated for active and latent tuberculosis infection.

Immunosuppression

There is currently a lack of clear and consistent conclusions on the effects of anti-interleukin-1 (IL-1) therapy on malignant CA. What is known is that the risk of CA may be increased when treated with canakinumab.

The main function of immunosuppressants is to suppress the function of the immune system to reduce inflammatory and autoimmune responses. This inhibitory effect may reduce the immune system's ability to monitor and eliminate abnormal cells, increasing the risk of CA. Patients who use immunosuppressants for a long time, especially those who are already at risk of malignant CA, are more likely to have recurrence or progression of malignant CA.

Immunization

Canakinumab is an inhibitor of interleukin-1β (IL-1β), which affects the normal function of the immune system. There is currently no data on the efficacy or risk of secondary infection transmission in patients receiving canakinumab after vaccination with live vaccines. Live virus vaccines should be avoided in combination with canakinumab while using canakinumab.

IL-1 blockade may interfere with the immune response to neoantigens. It is recommended that adults and children should receive all recommended vaccines before starting treatment with canakinumab, which can help patients build immune protection against common pathogens before the immune system is suppressed.

When using canakinumab, patients should follow their doctor's advice and pay attention to the above precautions to ensure safe and effective use of the drug.